Efficacy and Safety of Brentuximab Vedotin in Combination With Tislelizumab for the Treatment of CD30-positive Relapsed/Refractory NK/T-cell Lymphoma
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Brentuximab vedotin (Primary) ; Tislelizumab (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 12 Apr 2022 New trial record